eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | neurofibromatosis 2 |
| Comorbidity | C0027859|vestibular schwannomas |
| Sentences | 9 |
| PubMedID- 26377980 | Strategy for the surgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2. |
| PubMedID- 22483820 | The focus is on management of sporadic, unilateral vestibular schwannomas, because patients with neurofibromatosis type 2 pose different management problems best discussed separately. |
| PubMedID- 24393766 | Two phase ii clinical trials (nct01207687, nct01125046) are assessing the effectiveness of bevacizumab in treating neurofibromatosis 2 patients with symptomatic vestibular schwannomas and recurrent or progressive meningiomas. |
| PubMedID- 24718755 | Audiovestibular characteristics of small cochleovestibular schwannomas in neurofibromatosis type 2. |
| PubMedID- 24349188 | Five patients after bvds for bilateral vestibular schwannomas due to neurofibromatosis type ii (4 females and 1 male, age range = 39–60 years, m = 46.4 years, sd = 8.2), who did not have any functioning ear were tested with monocular dual-search coils in ludwig-maximilians university [18]. |
| PubMedID- 25567352 | Phase ii study of mtorc1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. |
| PubMedID- 24436903 | Six patients had neurofibromatosis type 2 (nf2) with bilateral vestibular schwannomas and meningiomas, and the four others had aggressive recurrent meningiomas. |
| PubMedID- 22681725 | Additionally, this method of drug delivery may have important implications in the treatment of patients with vestibular schwannomas associated with neurofibromatosis type 2. |
| PubMedID- 20150363 | Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. |
Page: 1